Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract

Trial Profile

Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Natalizumab (Primary) ; Methylprednisolone
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2016 According to ClinicalTrials.gov record, the treatment table has been updated.
    • 29 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Planned End Date changed from 1 Jul 2022 to 1 Mar 2020, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top